AUPH — Aurinia Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.12bn
- $834.85m
- $235.13m
- 87
- 26
- 87
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.07 | ||
| PEG Ratio (f) | 0.28 | ||
| EPS Growth (f) | 131.68% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.97 | ||
| Price to Tang. Book | 3 | ||
| Price to Free Cashflow | 25.41 | ||
| Price to Sales | 4.77 | ||
| EV to EBITDA | 58.74 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.03% | ||
| Return on Equity | 1.52% | ||
| Operating Margin | -1.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 50.12 | 45.6 | 134.03 | 175.51 | 235.13 | 257.87 | 322.24 | 274.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +176.31 | +68.16 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Directors
- George Milne CHM (77)
- Peter Greenleaf PRE (51)
- Joe Miller CFO (47)
- Stephen Robertson EVP (39)
- Matthew Donley EVP (52)
- Robert Huizinga EVP (56)
- Glenn Schulman SVP
- Neil Solomons CMO (53)
- Massimiliano Colao OTH (56)
- Michael Martin OTH (49)
- Brinda Balakrishnan DRC
- Daniel Billen DRC (67)
- R. Hector MacKay-Dunn DRC (69)
- Joseph Hagan IND (52)
- David Jayne IND (64)
- Jill Leversage IND (64)
- Timothy Walbert IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 27th, 2009
- Public Since
- July 16th, 2001
- No. of Shareholders
- 112
- No. of Employees
- 300
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 137,339,016
- Address
- #140, 14315 - 118 AVENUE, EDMONTON, T5L 4S6
- Web
- https://www.auriniapharma.com
- Phone
- +1 2507442487
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for AUPH
Aurinia Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Aurinia Pharmaceuticals Inc Earnings Release
Similar to AUPH
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Aurinia Pharmaceuticals share price?
As of Today at 18:26 UTC, shares in Aurinia Pharmaceuticals are trading at $8.16. This share price information is delayed by 15 minutes.
How has the Aurinia Pharmaceuticals share price performed this year?
Shares in Aurinia Pharmaceuticals last closed at $8.16 and the price had moved by +60.31% over the past 365 days. In terms of relative price strength the Aurinia Pharmaceuticals share price has outperformed the S&P500 Index by +45.48% over the past year.
What are the analyst and broker recommendations for Aurinia Pharmaceuticals?
The overall consensus recommendation for Aurinia Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aurinia Pharmaceuticals dividend yield?
Aurinia Pharmaceuticals does not currently pay a dividend.
Does Aurinia Pharmaceuticals pay a dividend?
Aurinia Pharmaceuticals does not currently pay a dividend.
When does Aurinia Pharmaceuticals next pay dividends?
Aurinia Pharmaceuticals does not currently pay a dividend.
How do I buy Aurinia Pharmaceuticals shares?
To buy shares in Aurinia Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aurinia Pharmaceuticals?
As of the previous close price of $8.16, shares in Aurinia Pharmaceuticals had a market capitalisation of $1.12bn.
Where are Aurinia Pharmaceuticals shares listed?
Here are the trading details for Aurinia Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AUPH
What kind of share is Aurinia Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Aurinia Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aurinia Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Aurinia Pharmaceuticals is $9.97. That is 22.18% above the last closing price of $8.16.
Analysts covering Aurinia Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.45 for the next financial year.
Find out moreWhat is the trend in the Aurinia Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurinia Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +15.95%.
As of the last closing price of $8.16, shares in Aurinia Pharmaceuticals were trading +13.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aurinia Pharmaceuticals PE Ratio?
The Aurinia Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 16.07. The shares last closed at $8.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' management team is headed by:
- George Milne - CHM
- Peter Greenleaf - PRE
- Joe Miller - CFO
- Stephen Robertson - EVP
- Matthew Donley - EVP
- Robert Huizinga - EVP
- Glenn Schulman - SVP
- Neil Solomons - CMO
- Massimiliano Colao - OTH
- Michael Martin - OTH
- Brinda Balakrishnan - DRC
- Daniel Billen - DRC
- R. Hector MacKay-Dunn - DRC
- Joseph Hagan - IND
- David Jayne - IND
- Jill Leversage - IND
- Timothy Walbert - IND